Atypical Teratoid Rhabdoid Tumor drugs in development, 2024

GlobalData tracks 18 drugs in development for Atypical Teratoid Rhabdoid Tumor by 16 companies/universities/institutes. The top development phase for Atypical Teratoid Rhabdoid Tumor is preclinical, with six drugs in that stage.

Bayer’s projects with Twist, Evotec; AbbVie buys out Parkinson’s drugmaker; A new drug discovery nonprofit in Toronto

Bayer teams up with Twist: The German drugmaker entered into a drug discovery deal with California biotech Twist Bioscience. Twist will use its synthetic antibody

October 6, 2023

Tech companies pitch AI platforms for healthcare, outline plans for responsible rollout

Listen to the article 8 min This audio is auto-generated. Please let us know if you have feedback. LAS VEGAS — Executives from America’s largest

November 1, 2024

PRO-1107 by ProfoundBio Suzhou for Gastric Cancer: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

April 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.